PHILADELPHIA – The interleukin-1 (IL-1) inhibitor goflikicept significantly reduced the level of high-sensitivity C-reactive protein (hs-CRP) in patients who underwent percutaneous coronary intervention (PCI) after ST-elevation myocardial infarction (STEMI), according to new phase 2 trial results.